Skip to content
OpenCapital
Get started

Zymeworks ZYME Cash received from option exercises

Cash received from option exercises at other companies

Charles River Laboratories logo
Charles River LaboratoriesCRL
$1.22M—

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.76B+125%
Enterprise value$1.53B+112%
P/S21.6×+13.2×

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's cash received from option exercises.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's cash received from option exercises?
Zymeworks (ZYME) reported cash received from option exercises of $8.72M in Q1 2026.
How has Zymeworks's cash received from option exercises changed year-over-year?
Zymeworks's cash received from option exercises increased by 1029.1% year-over-year, from $772K to $8.72M.
What does cash received from option exercises mean?
The total cash inflow generated from the exercise of employee or director stock options during the reporting period. This metric reflects the liquidity impact of equity-based compensation programs and employee participation in the company's stock performance.